149 related articles for article (PubMed ID: 36618907)
1. Discovery of potent and noncovalent KRAS
Wang Y; Zhang H; Li J; Niu MM; Zhou Y; Qu Y
Front Pharmacol; 2022; 13():1094887. PubMed ID: 36618907
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
[TBL] [Abstract][Full Text] [Related]
3. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
[TBL] [Abstract][Full Text] [Related]
4. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
[TBL] [Abstract][Full Text] [Related]
6. KRAS inhibitors: going noncovalent.
Drosten M; Barbacid M
Mol Oncol; 2022 Dec; 16(22):3911-3915. PubMed ID: 36383067
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of purine and pyrimidine-based
Park SY; Gowda Saralamma VV; Nale SD; Kim CJ; Jo YS; Baig MH; Cho J
Heliyon; 2024 Apr; 10(7):e28495. PubMed ID: 38617914
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-
Xiao X; Feng J; Ma J; Xia X; Liu X; Zhang J; Ding C; Pang X; Zhang A
J Med Chem; 2023 Nov; 66(22):15524-15549. PubMed ID: 37921024
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening.
Li L; Liu J; Yang Z; Zhao H; Deng B; Ren Y; Mai R; Huang J; Chen J
Eur J Med Chem; 2022 Apr; 233():114243. PubMed ID: 35276423
[TBL] [Abstract][Full Text] [Related]
10. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge.
Mao Z; Xiao H; Shen P; Yang Y; Xue J; Yang Y; Shang Y; Zhang L; Li X; Zhang Y; Du Y; Chen CC; Guo RT; Zhang Y
Cell Discov; 2022 Jan; 8(1):5. PubMed ID: 35075146
[TBL] [Abstract][Full Text] [Related]
11. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors.
Cheng H; Li P; Chen P; Irimia A; Bae JH; Brooun A; Fagan P; Lam R; Lin B; Zhang J; Zhan X; Wu X; Xie N; Chiang G; Shoemaker R; Vernier JM
ACS Med Chem Lett; 2023 Oct; 14(10):1351-1357. PubMed ID: 37849557
[TBL] [Abstract][Full Text] [Related]
13. Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant-Novel Insights from Computer-Aided Drug Discovery.
Ramalingam PS; Balakrishnan P; Rajendran S; Jothi A; Ramalingam R; Arumugam S
Curr Issues Mol Biol; 2023 Mar; 45(3):2136-2156. PubMed ID: 36975507
[TBL] [Abstract][Full Text] [Related]
14. Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer.
Jorgenson TC; Williams BR; Wendland A; Bilger A; Sandgren EP; Drinkwater NR
Cancer Res; 2010 Nov; 70(21):8398-406. PubMed ID: 20959479
[TBL] [Abstract][Full Text] [Related]
15. New lead compounds identification against KRas mediated cancers through pharmacophore-based virtual screening and in vitro assays.
Ghufran M; Rehman AU; Ayaz M; Ul-Haq Z; Uddin R; Azam SS; Wadood A
J Biomol Struct Dyn; 2023; 41(16):8053-8067. PubMed ID: 36184737
[TBL] [Abstract][Full Text] [Related]
16. Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors.
Sun R; Hu Y; Liu X; Lin Y; Lv D; Li W; Fu L; Jiang F
Bioorg Chem; 2024 Jul; 148():107460. PubMed ID: 38781668
[TBL] [Abstract][Full Text] [Related]
17. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
18. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
19. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Hu X; Zhang R; Yao J; Mu B; Zhao C
Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor efficacy of a potent and selective non-covalent KRAS
Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]